Reckitt Updates £10bn EMTN Programme With FCA-Approved Supplement

An update from Reckitt ( (GB:RKT) ) is now available.

Reckitt Benckiser Group has published a supplementary prospectus to its base prospectus for Reckitt Benckiser Treasury Services’ £10 billion Euro Medium Term Note Programme, which is guaranteed by the company. The document, approved by the UK Financial Conduct Authority and available via the National Storage Mechanism and Reckitt’s website, updates debt investors on the terms of the programme and reinforces the group’s access to euro-denominated capital markets, underlining its ongoing funding flexibility and engagement with fixed-income stakeholders.

The most recent analyst rating on (GB:RKT) stock is a Buy with a £60.00 price target. To see the full list of analyst forecasts on Reckitt stock, see the GB:RKT Stock Forecast page.

Spark’s Take on RKT Stock

According to Spark, TipRanks’ AI Analyst, RKT is a Neutral.

The score is driven primarily by improved financial performance (notably profitability and lower leverage) and supportive valuation (moderate P/E and solid yield). These are tempered by weak technicals (below key moving averages with negative momentum) and earnings-call-flagged near-term pressures on cash flow, leverage, and 2026 margin/EPS visibility.

To see Spark’s full report on RKT stock, click here.

More about Reckitt

Reckitt Benckiser Group is a global consumer goods company focused on health, hygiene and home care products. Its portfolio includes well-known brands such as Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet, with an emphasis on science-backed solutions that support cleaner, healthier living and sustainability.

Average Trading Volume: 2,310,959

Technical Sentiment Signal: Sell

Current Market Cap: £29.05B

Learn more about RKT stock on TipRanks’ Stock Analysis page.